DISCLAIMER: CONSULT WITH A DOCTOR BEFORE DECIDING ON A TREATMENT PLAN FOR ANY DISEASE OR INJURY.
Burton Immune Augmentation therapy was developed by Lawrence Burton, senior oncologist at St. Vincent’s Hospital in New York in conjunction with the Sloan Kettering Memorial Center in the 1950’s. He developed injections that caused tumors to shrink and cancer symptoms to go away. Burton later established the Immune Augmentation Therapy Clinic in the Bahamas where patients can go to receive his treatments.
Immune Augmentation Therapy (IAT) was developed in the 1960s by Lawrence Burton, Ph.D. as a method for restoring the body’s immune function to enable it to effectively fight cancer. According to Burton, the method isn’t meant to be used as a cure for cancer despite that in many cases tumors shrink and even disappear . The reason behind this statement is that the treatment doesn’t necessarily target the core cause of the cancer, meaning that the cancer could return under certain conditions. But, because IAT often reduces the size of tumors (or even gets rid of them completely), cancer patients can experience relief from their symptoms and effectively utilize other treatments to treat other potential core causes of their cancer (diet, environmental factors, etc.).
The United States’ OTA report on Burton’s IAT cancer treatment deemed it “one of the most widely known unconventional cancer treatments.” In the late 1960s, Burton demonstrated the effects of his treatment to a group of scientific and medical professionals, which resulted in newspaper headlines reading “15-Minute Cancer Cure” because of the treatment’s rapid functioning in reducing the size of tumors. However, after these demonstrations the American Cancer Society opted to place the treatment on their list of “unproven” cancer treatments .
In the late 1950s, Burton was working as a senior oncologist at St. Vincent’s Hospital in New York in conjunction with the Sloan-Kettering Cancer Center. Shortly after Burton’s research team discovered a protein factor in blood that was able to dramatically shrink or completely eradicate tumors in mice, the funding and grants from the Sloan-Kettering and other organizations were withdrawn and Burton was no longer able to get his research published in scientific and medical journals. In 1972, treatments at St. Vincent’s using Burton’s IAT methods were stopped on the basis that the treatments were “experimental, unproven, and not appropriate for use in medical care .”
When Burton sent in a request to start human trials of the treatment in 1975, the FDA replied with three questions that they required Burton to answer before they would allow him to start trials. According to Burton, he replied to the questions and sent them back, but the FDA stated that “no response to these questions was ever received…” despite the fact that after Burton’s response the FDA sent back 3 pages more of questions (single-spaced) in response. Instead of pursuing the request further, Burton moved his practice to the Bahamas and started working with human patients in his newly founded Immune Augmentation Therapy Clinic .
One article that appeared in the Cancer Journal for Clinicians states that “experts believe that the substances [Dr. Burton] claims to use cannot be produced by [injecting protein extracts isolated with processes he has patented] and have not been demonstrated to exist in the human body.” The article also mentioned the supposed lack of Burton’s exact methods, statistics, specimens of treatment materials, and that there have been no controlled clinical trials done on the treatment .
Safety and Effectiveness
Burton’s IAT cancer treatment has shown remarkably effective results in achieving cancer remission and elimination. In one group of 186 cancer patients (178 had been deemed terminal), 16% showed complete remission with no cancer evident while 43% showed tumor regression.
There are no noted side effects for Burton’s IAT treatment; the treatment is nontoxic and none of the patients who have undergone the treatment have exhibited or experienced adverse effects .
On a 1984 visit to the Immune Augmentation Therapy Clinic in the Bahamas, the following cases were observed in patients undergoing treatment using Burton’s immune augmentation cancer treatment:
- A 46-year-old male was diagnosed with stage 1B nodular sclerosing lymphoma in 1983, and underwent radiation and chemotherapy until October 1984 when he started IAT treatment after there was minimal change to his cancer. He completed 22 courses of IAT treatment and took numerous dietary supplements to support his immune system. During his IAT, a decrease in cancer mass was noticed via x-ray; in 1986 the tumor was deemed as an “inactive disease.” In 1996 the tumor maintained its status as an inactive disease, and as far as 2001 the man reported feeling and being of excellent condition and being able to go about his life with no real issue.
- A 68-year-old male was diagnosed with squamous cell carcinoma in and around his right vocal chord in 1981. This patient didn’t receive radiation or chemotherapy, and instead immediately started IAT treatment; he received 15 courses of the treatment between 1981 and 1989. In 1982 the cancer showed no progression or growth, and in 1984 there were no abnormalities present in the patient’s vocal cord region. In 2001 at the time of last contact, the man was in good health.
- A 50-year-old woman with peritoneal mesothelioma had had many surgeries and had briefly undergone Taxol-carboplatin chemotherapy (which she had an anaphylactic reaction to, thus halting the chemo). She started IAT treatment in 1999, and two different CT scans in 2001 showed tumor shrinkage and then the absence of any abnormalities. She has reported that she feels well and is in good health .
In the 1970s, it was observed that the following cancer types demonstrated the best chances of responding to IAT:
- Prostate cancer
- Malignant melanoma
- Bladder cancer
- Some head tumors
- Some neck tumors
- Mesothelioma 
How Burton Immune Augmentation is Administered
IAT is administered through a series of injections that contain proteins and other substances found in the patient’s own blood to strengthen the immune system’s natural functioning.
Regular blood tests are done for each patient to analyze the presence (or lack) of certain proteins and factors. After these analyses have been done with similar results for a few days, a patient-specific blood injection is made that contains the necessary components to strengthen the patient’s immune system, target cancer cells with particular antigens and antibodies, and eventually reduce tumor size.
IAT Protein Components
The treatment focuses on the interactions between four different protein components, which are:
1) the tumor antibody factor/tumor necrosis factor (TNF)
2) the tumor complement factor (an antigen released by tumor tissue)
3) the blocking protein
4) the deblocking protein
The TNF is the element that actually attacks the tumor, while the tumor complement factor is required to activate the TNF, which lies dormant until it is awakened by the tumor complement factor. The blocking protein inhibits the immune system from going to work on tumors too quickly to avoid the chance of the body going into shock and becoming overwhelmed with the processing of toxic waste released by the tumor. The deblocking protein allows the immune system to continue attacking the tumor, and is released and activated when the body deems it safe for tumor destruction to continue .
The above components of IAT treatment go by other names as well that are more familiar in mainstream cancer treatment and the scientific community. For example, the tumor antibody factor/TNF is a type of gamma globulin and/or some immunoglobulins like IgA and IgM .
IAT focuses on cytokines, which are special proteins that work with the immune system to signal to other cells to perform certain tasks at key times. A certain subset of cytokines work to cue the
TNF and tumor antibody factor when cancer occurs in the body. The TNF stops working against the cancer at a certain point, which Dr. Burton eventually discovered was because of the blocking proteins present in the blood. Burton’s Immune Augmentation treatment assumes that cancer growth is caused by imbalances of blocking and deblocking proteins that thus inhibit the body’s natural ability to fight and overcome the cancer; a lack of the tumor complement factor also inhibits the body’s ability to activate the tumor fighting TNF. By taking blood tests regularly during the treatment to analyze the presence of these specific factors and proteins, individuals administering the IAT treatment can figure out what specific combination of proteins each patient needs to give their immune system a necessary boost .
This immunotherapy treatment does not utilize factors/biological materials entirely from the patient for use in the injections. At the Immune Augmentation Therapy Clinic, the injections consist of:
- Tumor antibodies containing alpha-2 macroglobulin, IgG, IgM, and IgA obtained from a healthy donor without cancer.
- Tumor complement obtained from a donor with cancer. Individuals who have undergone chemotherapy or who have taken high doses of corticosteroids have lower levels of tumor complement in their blood, and thus may require more of this factor in their injections.
- Deblocking protein from the serum of a donor without cancer. The deblocking protein is an alpha-2 macroglobulin that combines with the blocking protein to allow the tumor complement to bind to the tumor antibody, thus allowing cancer destruction. Radiation lowers individuals’ levels of deblocking protein .
Other Important Information
The Immune Augmentation Therapy Clinic in Freeport, Grand Bahama in the Bahamas is one of the only clinics that specifically offers Burton’s IAT treatment. The clinic was opened by Dr. Burton in 1977. In addition to offering IAT, they also offer angiogenesis inhibition, apoptosis inducing agents, and cytotoxic agents.
Immune Augmentation Therapy Clinic/Quantum Immunologics
East Atlantic Drive
As mentioned at the beginning of this entry, Burton’s IAT treatment isn’t recommended to be used as a sole cancer cure. It should be used only in tandem with other treatments. It works to bring the cancer under control and to boost the body’s immune system to allow other treatments that treat core causes of cancer to do their work more effectively. Some sources note that maintenance doses of IAT treatment can ward off cancer, however this still isn’t treating the root of the cancer, just maintaining it through the natural activation of proteins and factors already existent in the body. Patients are advised to use this treatment only in combination with other cancer treatments to create a comprehensive cancer protocol.
 Pelton, Ross, R.Ph.; Overholser, Lee (1994). Immuno-Augmentive Therapy (IAT). Retrieved May 11, 2018 from: https://www.curezone.org/diseases/cancer/iat.asp
 N.A. (n.d) Questionable Methods of Cancer Management: Immuno-augmentive Therapy (IAT). Retrieved May 11, 2018 from: https://onlinelibrary.wiley.com/doi/pdf/10.3322/canjclin.41.6.357
 Euler, Lee (2015). A Pioneering Immune Therapy was Rejected by the U.S. Cancer Industry. Retrieved May 11, 2018 from: https://www.cancerdefeated.com/a-pioneering-immune-therapy-was-rejected-by-the-u-s-cancer-industry/3275/
 Moss, Ralph (2011). A visit to the IAT clinic. Retrieved May 15, 2018 from: http://www.biomedsearch.com/article/visit-to-IAT-clinic/255389350.html
 N.A. (n.d). Immune Augmentive Therapy Clinic. Retrieved May 15, 2018 from: http://immunemedicine.com/available-therapies/immune-augmentive-therapy/